Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Radonjic, Marijana ^a,b   de Haan, Jorn R ^a,b   van Erk, Marjan J ^a,b   van Dijk, Ko Willems ^a,c   van den Berg, Sjoerd A A ^a,c   de Groot, Philip J ^a,d   Müller, Michael ^a,d   van Ommen, Ben ^a,b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E3; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPOSURE; GENE ACTIVATION; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC TRANSCRIPTION; GENOME ANALYSIS; INFLAMMATION; LIPID DIET; LIPID STORAGE; LIVER; LONG TERM EXPOSURE; MICROARRAY ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; SHORT TERM EXPOSURE; STEATOSIS; TRANSGENIC MOUSE; ADAPTATION; ANIMAL; BLOOD; FAT INTAKE; FATTY LIVER; GENETICS; GENOME; MALE; METABOLISM; MOUSE;

MUS;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BLOOD PROTEINS; DIETARY FATS; FATTY LIVER; GENOME; LIVER; MALE; MICE; MICE, TRANSGENIC; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 69949089784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006646     Document Type: Article

References (84)

1. Kopelman PG (2000) Obesity as a medical problem. Nature 404: 635-643.
2. Kopelman PG, Grace C (2004) New thoughts on managing obesity. Gut 53: 1044-1053.
3. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM (2007) The epidemiology of obesity. Gastroenterology 132: 2087-2102.
4. Lissner L, Heitmann BL (1995) Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr 49: 79-90.
5. Buettner R, Scholmerich J, Bollheimer LC (2007) High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 15: 798-808.
6. Olefsky J, Reaven GM, Farquhar JW (1974) Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 53: 64-76.
7. Lin S, Thomas TC, Storlien LH, Huang XF (2000) Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 24: 639-646.
8. Muller M, Kersten S (2003) Nutrigenomics: goals and strategies. Nat Rev Genet 4: 315-322.
9. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454: 428-435.
10. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
11. Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454: 470-477.
12. Delerive P, De BK, Besnard S, Vanden BW, Peters JM, et al. (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NFkappaB and AP-1. J Biol Chem 274: 32048-32054.
13. Gervois P, Fruchart JC, Staels B (2007) Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 3: 145-156.
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956.
15. Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28: 551-558.
16. Duivenvoorden I, Teusink B, Rensen PC, Kuipers F, Romijn JA, et al. (2005) Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. J Lipid Res 46: 988-993.
17. Gijbels MJ, van der CM, van der Laan LJ, Emeis JJ, Havekes LM, et al. (1999) Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis 143: 15-25.
18. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, et al. (2004) Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109: 393-398.
19. Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, et al. (2007) Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 8: R200.
20. Kreeft AJ, Moen CJ, Hofker MH, Frants RR, Vreugdenhil E, et al. (2001) Identification of differentially regulated genes in mildly hyperlipidemic ApoE3-Leiden mice by use of serial analysis of gene expression. Arterioscler Thromb Vasc Biol 21: 1984-1990.
21. Kreeft AJ, Moen CJ, Porter G, Kasanmoentalib S, Sverdlov R, et al. (2005) Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. Atherosclerosis 182: 249-257.
22. van der Hoorn JW, Jukema JW, Bekkers ME, Princen HM, Corda S, et al. (2008) Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Crit Care Med 36: 2576-2582.
23. Wouters K, Shiri-Sverdlov R, van Gorp PJ, van BM, Hofker MH (2005) Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med 43: 470-479.
24. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, de BI, van VB, et al. (1993) Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 268: 10540-10545.
25. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der BH, HogenEsch H, et al. (1994) Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93: 1403-1410.
26. NuGO microarray information page. Available: http:// blog.bigcat.unimaas.nl/,martijn/NuGO/. Accessed 2008.
27. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
28. Ma P, Castillo-Davis CI, Zhong W, Liu JS (2006) A data-driven clustering method for time course gene expression data. Nucleic Acids Res 34: 1261-1269.
29. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: 3.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
31. Ingenuity® Systems. Available: www.ingenuity.com. Accessed 2008.
32. Koj A (1996) Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta 1317: 84-94.
33. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10: 45-65.
34. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, et al. (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278: 34268-34276.
35. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, et al. (2005) Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336: 215-222.
36. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152.
37. Matsusue K, Kusakabe T, Noguchi T, Takiguchi S, Suzuki T, et al. (2008) Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab 7: 302-311.
38. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, et al. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) over-expression. J Biol Chem 278: 498-505.
39. Luedde T, Beraza N, Kotsikoris V, van LG, Nenci A, et al. (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132.
40. Wunderlich FT, Luedde T, Singer S, Schmidt-Supprian M, Baumgartl J, et al. (2008) Hepatic NF-kappaB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci U S A 105: 1297-1302.
41. Karin M (1999) The beginning of the end: IkappaB kinase (IKK) and NFkappaB activation. J Biol Chem 274: 27339-27342.
42. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, et al. (1998) Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93: 1231-1240.
43. Duque N, Gomez-Guerrero C, Egido J (1997) Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 159: 3474-3482.
44. Ouadrhiri Y, Pilette C, Monteiro RC, Vaerman JP, Sibille Y (2002) Effect of IgA on respiratory burst and cytokine release by human alveolar macrophages: role of ERK1/2 mitogen-activated protein kinases and NF-kappaB. Am J Respir Cell Mol Biol 26: 315-332.
45. Drew PD, Franzoso G, Carlson LM, Biddison WE, Siebenlist U, et al. (1995) Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin gene expression in transfected human neuroblastoma cells. J Neuroimmunol 63: 157-162.
46. Gobin SJ, Biesta P, Van den Elsen PJ (2003) Regulation of human beta 2-microglobulin transactivation in hematopoietic cells. Blood 101: 3058-3064.
47. Poole E, Atkins E, Nakayama T, Yoshie O, Groves I, et al. (2008) NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86. J Virol 82: 4250-4256.
48. Pang H, Lin A, Holford M, Enerson BE, Lu B, et al. (2006) Pathway analysis using random forests classification and regression. Bioinformatics 22: 2028-2036.
49. az-Uriarte R, varez de AS (2006) Gene selection and classification of microarray data using random forest. BMC Bioinformatics 7: 3.
50. Uchinami H, Seki E, Brenner DA, D'Armiento J (2006) Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44: 420-429.
51. Read R, Hansen G, Kramer J, Finch R, Li L, et al. (2009) Ectonucleoside triphosphate diphosphohydrolase type 5 (Entpd5) deficient mice develop progressive hepatopathy, hepatocellular tumors and spermatogenic arrest. Vet Pathol.
52. Rodriguez JA, Buzaleh AM, Fossati M, Azcurra J, Batlle AM (2002) The effects of some porphyrinogenic drugs on the brain cholinergic system. Cell Mol Biol (Noisy -le-grand) 48: 103-110.
53. Iwasaki T, Yoneda M, Nakajima A, Terauchi Y (2007) Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 46: 1633-1639.
54. Cardona F, Tunez I, Tasset I, Montilla P, Collantes E, et al. (2008) Fat overload aggravates oxidative stress in patients with the metabolic syndrome. Eur J Clin Invest 38: 510-515.
55. Miyazaki M, Dobrzyn A, Sampath H, Lee SH, Man WC, et al. (2004) Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha. J Biol Chem 279: 35017-35024.
56. Meng F, Liu L, Chin PC, D'Mello SR (2002) Akt is a downstream target of NF-kappa B. J Biol Chem 277: 29674-29680.
57. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, et al. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
58. Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in antiapoptotic PDGF signalling. Nature 401: 86-90.
59. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
60. Spiegelman BM, Flier JS (1996) Adipogenesis and obesity: rounding out the big picture. Cell 87: 377-389.
61. Kim JB, Spiegelman BM (1996) ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 10: 1096-1107.
62. Suzawa M, Takada I, Yanagisawa J, Ohtake F, Ogawa S, et al. (2003) Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/ TAB1/ NIK cascade. Nat Cell Biol 5: 224-230.
63. Ricote M, Glass CK (2007) PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771: 926-935.
64. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, et al. (2003) Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171: 6827-6837.
65. Straus DS, Pascual G, Li M, Welch JS, Ricote M, et al. (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 97: 4844-4849.
66. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, et al. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108.
67. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119.
68. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190.
69. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
70. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, et al. (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531.
71. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, et al. (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21: 365-371.
72. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, et al. (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679-684.
73. Kuenzli S, Saurat JH (2003) Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 149: 229-236.
74. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, et al. (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389.
75. ArrayExpress repository. Available: www.ebi.ac.uk/arrayexpress/. Accessed 2008.
76. The R Project for Statistical Computing. Available: http://www.r-project.org/. Accessed 2008.
77. Bioconductor. Available: http://www.bioconductor.org/. Accessed 2008.
78. Management and Analysis Database for MicroArray eXperiments (MADMAX). Available: https://madmax.bioinformatics.nl. Accessed 2008.
79. Molecular and Behavioral Neuroscience Institute. Available: http:// brainarray.mbni.med.umich.edu/. Accessed 2008.
80. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al. (2005) Evolving gene/ transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175.
81. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
82. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
83. de Hoon MJ, Imoto S, Nolan J, Miyano S (2004) Open source clustering software. Bioinformatics 20: 1453-1454.
84. Liaw A, Wiener M (2002) Classification and Regression by random-Forest. R News 2: 18-22.